Effect of early two-dose measles vaccination on childhood mortality and modification by maternal measles antibody in Guinea-Bissau, West Africa: A single-centre open-label randomised controlled trial

BACKGROUND: Early 2-dose measles vaccine (MV) at 4 and 9 months of age vs. the WHO strategy of MV at 9 months of age reduced all-cause child mortality in a previous trial. We aimed to test two hypotheses: 1) a 2-dose strategy reduces child mortality between 4 and 60 months of age by 30%; 2) receivin...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Sebastian, Fisker, Ane B, da Silva, Isaquel, Byberg, Stine, Biering-Sørensen, Sofie, Balé, Carlitos, Barbosa, Amarildo, Bjerregaard-Andersen, Morten, Hansen, Nadja Skadkær, Do, Vu An, Bæk, Ole, Rasmussen, Stine Møller, Damkjær, Lone, Hvidt, Sophus, Baltzersen, Olga, Rodrigues, Amabelia, Martins, Cesario, Jensen, Kristoffer J, Whittle, Hilton C, Smits, Gaby, van der Klis, Fiona, Aaby, Peter, Benn, Christine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156892/
https://www.ncbi.nlm.nih.gov/pubmed/35747181
http://dx.doi.org/10.1016/j.eclinm.2022.101467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156892/
https://www.ncbi.nlm.nih.gov/pubmed/35747181
http://dx.doi.org/10.1016/j.eclinm.2022.101467

Ejemplares similares